Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1984; 52(02): 157-159
DOI: 10.1055/s-0038-1661162
DOI: 10.1055/s-0038-1661162
Original Article
Clearance and In Vivo Release by Heparin of Human Platelet Factor 4 (PF4) in the Rabbit
Authors
Further Information
Publication History
Received 22 June 1984
Accepted 03 July 1984
Publication Date:
19 July 2018 (online)
Summary
13 male New Zealand rabbits were injected with two different doses (25 μg/Kg and 100 μg/Kg) of human platelet factor 4 antigen (PF4). The disappearance of the protein was extremely fast with an half-life for the fast component of 1.07 ± 0.16 and 1.76 ± 0.11 min respectively. The half-life for the slow component, detectable only with the highest dosage, was 18.8 min.
The administration of 2500 I.U. of heparin 30 min after PF4 administration induced a partial release of the injected protein and its clearance from plasma was slow, with half-life of 23.3 ± 5.9 min and 30.9 ± 2.19 min respectively.
-
References
- 1 Niewiarowski S, Varma KG. Biochemistry and physiology of secreted platelet proteins. In: Hemostasis and Thrombosis. Basic principles and clinical pratice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (Eds) J B Lippincott Company; Philadelphia - Toronto: 1983. pp 421-430
- 2 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human P-thromboglobulin and platelet factor 4. Thromb Res 1968; 12: 851-861
- 3 Musial J, Niewiarowski S, Edmunds Jr LH, Addonizio Jr VP, Nicolau KC, Colman RW. In vivo release and turnover of secreted platelet antiheparin proteins in rhesus monkey (macaca mulatta). Blood 1980; 56: 596-603
- 4 Rao AK, Niewiarowski S, James P, Holt JC, Harris H, Helfenbein B, Basti C. Effect of heparin on in vivo release and clearance of human platelet factor 4. Blood 1983; 61: 1208-1214
- 5 Celia G, Menardo A, Girolami A. Effects of heparins on in vivo platelet factor 4 (PF4) release and platelet aggregation after aspirin administration. Clin Lab Haematol 1980; 2: 333-338
- 6 Celia G, Colby SI, Taylor AD, McCracken L, Parisi AF, Sasahara AA. Platelet factor 4 (PF4) and heparin-released platelet factor 4 (HR- PF4) in patients with vascular disorders. Thromb Res 1983; 29: 499-509
- 7 Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res 1980; 19: 129-137
- 8 Dawes J, Pumphrey CW, McLaren CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76
- 9 Rucinski B, Niewiarowski S, Pranee J, Walz DA, Rudzynski AZ. Antiheparin proteins secreted by human platelets. Purification, characterization and radioimmunoassay Blood 1979; 53: 47-62
- 10 Celia G, Vitadello O, Gallucci V, Girolami A. The release of β- Thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery. Eur J Clin Invest 1981; 11: 165-169
- 11 Fabrizi P, Barbarulli G, Castellani M, Tarli P. Indentity between human and monkey platelet factor 4 antigen (s) in a RIA system. Thromb Res 1981; 21: 165-168
- 12 Mitruka BM, Rawnsley HM. Clinical, biochemical and haematological reference values in normal experimental animals and normal humans. 2. Ed Masson Pub; New York: 1981. pp 1-8
- 13 Wight TN. Vessel proteoglycans and thrombogenesis. In: Progress in Hemostasis and Thrombosis. Spaet TH. (Ed.) Grune and Stratton, New York. 1980. 5 1-39